司库奇尤单抗阻断IL-17A对银屑病关节炎的长期骨保护效应:PSARTROS-II研究
PSARTROS-II研究为IV期非干预研究,纳入32例活动性银屑病关节炎(PsA)成人患者,接受司库奇尤单抗治疗并随访48个月,采用高分辨率外周定量CT(HR-pQCT)和手部MRI评估骨结构变化。结果显示药物48个月生存率68.8%,各临床疾病领域显著改善,HR-pQCT示骨密度、微结构和生物力学得以保持,骨侵蚀无进展,MRI炎症改变持续低水平,无重大安全信号。
要点
- 司库奇尤单抗治疗48个月药物生存率68.8%,各PsA疾病领域显著改善。
- HR-pQCT显示骨密度、微结构和生物力学保持,骨侵蚀无进展。
- MRI示PsAMRIS侵蚀和骨增殖子项轻度增加,炎症改变持续低水平。
核心结论
- 多模态影像显示司库奇尤单抗治疗48个月期间PsA患者结构骨损伤无相关进展,提示抗IL-17A治疗诱导持续骨保护效应。
研究设计与样本
- IV期非干预研究,纳入32例活动性PsA成人患者,接受司库奇尤单抗治疗并按临床实践随访48个月,重复HR-pQCT和手部MRI评估。
主要发现
- 48个月药物生存率为68.8%。
- 疾病活动度评分28(DAS28)显著改善(p<0.001),利兹附着点炎指数(p=0.027)、银屑病面积和严重程度指数(p=0.001)、银屑病关节炎疾病影响(p<0.001)和疼痛(p<0.001)均显著改善,C反应蛋白(p=0.09)变化。
- 健康评估问卷(HAQ)功能状态保持稳定。
- HR-pQCT示骨密度、微结构和生物力学得以保持,骨侵蚀无进展(所有变化均不显著)。
- MRI示PsAMRIS侵蚀和骨增殖子项分别轻度增加(+1.4和+0.8),炎症改变持续低水平;无重大安全信号。
关键数值与推荐
- 药物48个月生存率68.8%。
- DAS28改善p<0.001,利兹附着点炎指数p=0.027,PASI p=0.001,CRP p=0.09,PsAID p<0.001,疼痛p<0.001。
- MRI PsAMRIS侵蚀子项增加+1.4,骨增殖子项增加+0.8。
临床怎么用
- 在活动性PsA患者中,司库奇尤单抗治疗48个月可维持骨密度和微结构、阻止骨侵蚀进展,并持续控制炎症和改善临床症状。
局限性
- 样本量较小(32例),为非干预研究,结果需在更大样本中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the long-term efficacy of interleukin (IL)-17A inhibition with secukinumab on structural bone changes and clinical outcomes in psoriatic arthritis (PsA). METHODS: We conducted a phase-IV non-interventional study on adult patients with active PsA using high-resolution peripheral quantitative CT (HR-pQCT) and MRI of the hand over 48 months. All participants received secukinumab treatment and were followed up according to clinical practice, with repeated HR-pQCT and MRI. Number and volume of erosions, bone density, cortical and trabecular microarchitecture and bone biomechanical properties were assessed based on HR-pQCT scans. MRI synovitis, tenosynovitis, osteitis, periarticular inflammation, erosions and osteoproliferation were quantified by Psoriatic Arthritis MRI Score (PsAMRIS)-Outcome Measures in Rheumatology (OMERACT) score. Study outcomes included drug survival and changes from baseline in disease activity, functional status and imaging-detected inflammation and damage. RESULTS: 32 patients with PsA (40.6% female, mean age 56±7.5 years) were enrolled. Drug survival rate was 68.8% at 48 months. Secukinumab was highly effective in all PsA disease domains, with significant improvements in Disease Activity Score 28 (p<0.001), Leeds Enthesitis Index (p=0.027), Psoriasis Area and Severity Index (p=0.001), C reactive protein (p=0.09), Psoriatic Arthritis Impact of Disease (p<0.001) and pain (p<0.001). Functional status measured by the Health Assessment Questionnaire remained stable. On HR-pQCT, bone density, microarchitecture and biomechanics were preserved. There was no progression of bone erosions (all changes were not significant). On MRI, PsAMRIS erosion and osteoproliferation subitems increased marginally (+1.4 and +0.8, respectively), while inflammatory changes remained stably low. No major safety signals emerged. CONCLUSION: Multimodal imaging with HR-pQCT and MRI showed no relevant progression of structural bone damage over 48 months in patients with PsA treated with secukinumab, suggesting that anti-IL-17A therapy induces sustained osteoprotective effects in PsA.
引用
- Schuster L, Temiz A, Mutlu MY, et al. Long-term osteoprotective effects of IL-17A blockade with secukinumab in psoriatic arthritis: data from the PSARTROS-II study. RMD Open. 2026. PMID: 41741168. doi:10.1136/rmdopen-2025-005857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。